Talking Medicines mission is to be the world’s gold standard provider of patient intelligence by medicine, and its vision is better health outcomes for every patient.
Through a combination of Artificial Intelligence and industry expertise, Talking Medicines has developed the next generation data platform to bring social listening for pharmaceutical companies into the new age. Its platform PatientMetRx® is driven by Artificial Intelligence models that use machine learning and natural language processing, to scale real world data collection to a scale that is transformational versus traditional research.
While Talking Medicines encourages patients to take their medicines correctly, it also disrupts how pharmaceutical companies access real-world data, by allowing them to see how their medicines are actually being used.
By structuring and translating the patient’s voice into a Patient Confidence Score (PCS), Talking Medicines helps pharma understand patient confidence in their medicines driving marketing excellence and ultimately delivering better patient outcomes. Talking Medicines puts the Patient Voice at the heart of pharma planning and strategy.
The total raised by Talking Medicines to date is £4 million. The company is focusing this year on expanding its PatientMetRx® subscription base amongst pharma brand teams, and pharma marketing agencies, in the US as well as UK.
Medical device specialist Nebu~Flow secures £1.7m investmentRead more about Medical device specialist Nebu~Flow secures £1.7m investment
Carcinotech secures £1.6m of new investment from leading Scottish investorsRead more about Carcinotech secures £1.6m of new investment from leading Scottish investors
Good-Loop accelerates US expansion plans after closing $6.1M Series A roundRead more about Good-Loop accelerates US expansion plans after closing $6.1M Series A round